心血管病患者载脂蛋白CIII升高与缺血性脑血管事件风险增加相关
研究纳入950例有或无冠状动脉疾病的心血管病患者,随访中位130个月,发现Apo CIII高于中位数10.6 mg/dL者发生缺血性卒中/TIA的风险约增加2倍(HR 2.23,95%CI 1.21-4.13),提示高Apo CIII可预测缺血性脑血管事件风险。
要点
- Apo CIII高于中位数10.6 mg/dL与卒中/TIA风险约2倍增加独立相关
- 该关联在CAD与非CAD人群中分别验证,并经倾向评分匹配确认
- Apo CIII或可作为心血管患者缺血性卒中/TIA的风险预测指标
核心结论
- 高血浆Apo CIII浓度可能预测心血管患者缺血性卒中/TIA风险增加。
研究设计与样本
- 前瞻性队列研究,纳入950例受试者(中位年龄65岁,30.7%女性),其中CAD 774例、无CAD 176例。
- 入组时检测全部受试者的血浆脂质和载脂蛋白谱,包括Apo A-I、B、CIII和E。
主要发现
- 中位随访130个月(四分位距69-189)后,95例(10%)发生缺血性卒中/TIA事件。
- 卒中/TIA患者入组时Apo CIII血浆浓度(11.4 mg/dL,四分位距9.3-14.4)高于无卒中/TIA者(10.4 mg/dL,四分位距8.7-13.0)。
- Apo CIII高于中位值10.6 mg/dL者卒中/TIA风险约增加2倍,校正混杂因素后HR为2.23(95%CI 1.21-4.13)。
- 该结果在CAD和无CAD人群中分别得到确认,并经倾向评分匹配(98例CAD与98例无CAD一对一匹配)验证。
关键数值与推荐
- Apo CIII中位值为10.6 mg/dL,高于此值定义为高Apo CIII。
- 校正包括性别、年龄、CAD诊断、高血压、心房颤动、口服抗凝治疗及所有血浆脂质参数后,HR为2.23(95%CI 1.21-4.13)。
临床怎么用
- 在心血管病患者中,可考虑检测血浆Apo CIII以辅助评估缺血性卒中/TIA风险。
- Apo CIII升高提示需加强脑血管事件风险评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Apo CIII (apolipoprotein CIII), a crucial regulator of lipoprotein metabolism, has been associated with increased activity of coagulation factors and thrombin generation and, in turn, with an increased risk of thromboembolic events in both arterial and venous districts. Thus, we hypothesized that it may affect the risk of acute ischemic cerebrovascular events in cardiovascular patients. Methods- We systematically checked medical records and quantified cerebral ischemic events in a cohort of 950 subjects (median age 65 with interquartile range, 55-79 years; 30.7% females) with or without angiographically defined coronary artery disease (CAD: 774 CAD and 176 CAD-free, respectively). All the subjects, enrolled between May 1999 and December 2006, were prospectively followed until death or July 31, 2018. Assessments of complete plasma lipid and apolipoprotein profiles, including Apo A-I, B, CIII, and E, were available for all subjects at enrollment. Results- After a median follow-up of 130 months (interquartile range, 69-189), 95 subjects (10%) suffered ischemic stroke/transient ischemic attack (TIA) events. Stroke/TIA subjects had higher Apo CIII plasma concentration (11.4; interquartile range: 9.3-14.4 mg/dL) at enrollment than those without stroke/TIA (10.4, interquartile range: 8.7-13.0 mg/dL). Subjects with Apo CIII levels above the median value (10.6 mg/dL) exhibited an ≈2-fold increased risk of stroke/TIA, even after adjustment for potential confounders, including sex, age, CAD diagnosis, hypertension, atrial fibrillation, oral anticoagulant treatment, and all plasma lipid parameters (hazard ratio: 2.23 [95% CI, 1.21-4.13]). This result was confirmed in CAD and CAD-free populations, separately, and even by a propensity score matching method, in which 98 CAD and 98 CAD-free subjects were one-to-one matched for all clinical and laboratory characteristics. Conclusions- These findings suggest that a high Apo CIII plasma concentration may predict an increased risk of ischemic stroke/TIA in cardiovascular patients.
引用
- Olivieri O, Cappellari M, Turcato G, et al. Increased Incidence of Ischemic Cerebrovascular Events in Cardiovascular Patients With Elevated Apolipoprotein CIII. Stroke. 2019. PMID: 31795904. doi:10.1161/STROKEAHA.119.026811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。